Genfit Balans Gezondheid

Financiële gezondheid criteriumcontroles 5/6

Genfit heeft een totaal eigen vermogen van €69.2M en een totale schuld van €57.1M, wat de schuld-eigenvermogensverhouding op 82.4% brengt. De totale activa en totale passiva bedragen respectievelijk €151.4M en €82.2M. De EBIT Genfit is €3.0M waardoor de rentedekking 1 is. Het heeft contanten en kortetermijnbeleggingen van €81.8M.

Belangrijke informatie

82.45%

Verhouding schuld/eigen vermogen

€57.07m

Schuld

Rente dekkingsratio	1x
Contant	€81.79m
Aandelen	€69.22m
Totaal verplichtingen	€82.20m
Totaal activa	€151.42m

Recente financiële gezondheidsupdates

Recent updates

Improved Revenues Required Before Genfit S.A. (EPA:GNFT) Stock's 29% Jump Looks Justified

May 06

Solid Earnings Reflect Genfit's (EPA:GNFT) Strength As A Business

May 02

These 4 Measures Indicate That Genfit (EPA:GNFT) Is Using Debt Reasonably Well

Apr 29

Genfit S.A. (EPA:GNFT) Not Doing Enough For Some Investors As Its Shares Slump 25%

Nov 16

We Think Shareholders Should Be Aware Of Some Factors Beyond Genfit's (EPA:GNFT) Profit

Sep 27

Genfit S.A. (EPA:GNFT) Held Back By Insufficient Growth Even After Shares Climb 26%

Sep 26

Growth Investors: Industry Analysts Just Upgraded Their Genfit S.A. (EPA:GNFT) Revenue Forecasts By 28%

Sep 24

Genfit (EPA:GNFT) Seems To Use Debt Quite Sensibly

Sep 22

Genfit S.A.'s (EPA:GNFT) Price Is Right But Growth Is Lacking After Shares Rocket 28%

May 23

Genfit S.A.'s (EPA:GNFT) 26% Price Boost Is Out Of Tune With Revenues

Jan 03

Health Check: How Prudently Does Genfit (EPA:GNFT) Use Debt?

Sep 22

Revenue Downgrade: Here's What Analysts Forecast For Genfit S.A. (EPA:GNFT)

Jul 05

Genfit S.A. (EPA:GNFT) Investors Are Less Pessimistic Than Expected

Jun 23

We Think Genfit (EPA:GNFT) Can Manage Its Debt With Ease

Dec 28

New Forecasts: Here's What Analysts Think The Future Holds For Genfit S.A. (EPA:GNFT)

Sep 30

Downgrade: Here's How Analysts See Genfit S.A. (EPA:GNFT) Performing In The Near Term

Jun 29

Genfit's(EPA:GNFT) Share Price Is Down 85% Over The Past Five Years.

Mar 14

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( €92.8M ) GNFT } overtreffen de korte termijn passiva ( €75.2M ).

Langlopende schulden: De kortetermijnactiva GNFT ( €92.8M ) overtreffen de langetermijnschulden ( €7.0M ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: GNFT heeft meer geld in kas dan de totale schuld.

Schuld verminderen: De schuld/eigen vermogen-ratio van GNFT is de afgelopen 5 jaar gedaald van 203.8% naar 82.4%.

Schuldendekking: De schuld van GNFT wordt goed gedekt door de operationele kasstroom ( 27.2% ).

Rentedekking: De rentebetalingen van GNFT op haar schulden worden niet goed gedekt door EBIT ( 1 x dekking).

Balans

Ontdek gezonde bedrijven

Bedrijfsanalyse en status van financiële gegevens

Gegevens	Laatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse	2025/05/20 07:11
Aandelenkoers aan het einde van de dag	2025/05/20 00:00
Inkomsten	2024/12/31
Jaarlijkse inkomsten	2024/12/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

Pakket	Gegevens	Tijdframe	Voorbeeld Amerikaanse bron ^*
Financiële gegevens bedrijf	10 jaar	Resultatenrekening Kasstroomoverzicht Balans	SEC-formulier 10-K SEC-formulier 10-Q
Consensus schattingen analisten	+3 jaar	Financiële prognoses Koersdoelen analisten	Onderzoeksrapporten van analisten Blue Matrix
Marktprijzen	30 jaar	Aandelenprijzen Dividenden, splitsingen en acties	ICE Marktgegevens SEC-formulier S-1
Eigendom	10 jaar	Top aandeelhouders Handel met voorkennis	SEC-formulier 4 SEC-formulier 13D
Beheer	10 jaar	Leiderschapsteam Raad van bestuur	SEC-formulier 10-K SEC-formulier DEF 14A
Belangrijkste ontwikkelingen	10 jaar	Bedrijfsaankondigingen	SEC-formulier 8-K

^* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren, zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen voor het gebruik van onze rapporten en tutorials op Youtube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

Genfit S.A. wordt gevolgd door 14 analisten. 3 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

Analist	Instelling
Geoffrey Meacham	BofA Global Research
Jean-Jacques Le Fur	Bryan Garnier & Co
Arnaud Cadart	CIC Market Solutions (ESN)

Genfit Balans Gezondheid

Financiële gezondheid criteriumcontroles 5/6

Belangrijke informatie

Recente financiële gezondheidsupdates

These 4 Measures Indicate That Genfit (EPA:GNFT) Is Using Debt Reasonably Well

Genfit (EPA:GNFT) Seems To Use Debt Quite Sensibly

Health Check: How Prudently Does Genfit (EPA:GNFT) Use Debt?

We Think Genfit (EPA:GNFT) Can Manage Its Debt With Ease

Recent updates

Improved Revenues Required Before Genfit S.A. (EPA:GNFT) Stock's 29% Jump Looks Justified

Solid Earnings Reflect Genfit's (EPA:GNFT) Strength As A Business

Genfit S.A. Announces Efficacy Results of Ipsen’s Phase 2 ELMWOOD Trial

These 4 Measures Indicate That Genfit (EPA:GNFT) Is Using Debt Reasonably Well

Full year 2024 earnings released: EPS: €0.03 (vs €0.58 loss in FY 2023)

Consensus EPS estimates fall by 54%

New major risk - Revenue and earnings growth

GENFIT Outlines Anticipated New Clinical Trial Initiations, Development Milestones and Data Readouts in 2025

Genfit S.A., Annual General Meeting, Jun 17, 2025

Genfit S.A. to Report Fiscal Year 2024 Results on Apr 24, 2025

Genfit S.A. (EPA:GNFT) Not Doing Enough For Some Investors As Its Shares Slump 25%

Investor sentiment deteriorates as stock falls 20%

Consensus EPS estimates increase by 21%, revenue downgraded

We Think Shareholders Should Be Aware Of Some Factors Beyond Genfit's (EPA:GNFT) Profit

Investor sentiment improves as stock rises 26%

Genfit S.A. (EPA:GNFT) Held Back By Insufficient Growth Even After Shares Climb 26%

First half 2024 earnings: EPS and revenues exceed analyst expectations

Growth Investors: Industry Analysts Just Upgraded Their Genfit S.A. (EPA:GNFT) Revenue Forecasts By 28%

Genfit (EPA:GNFT) Seems To Use Debt Quite Sensibly

Genfit S.A. Announces the Successful Corporate Milestone with U.S. FDA Accelerated Approval of Ipsen's Iqirvo for Primary Biliary Cholangitis

New minor risk - Share price stability

Genfit S.A.'s (EPA:GNFT) Price Is Right But Growth Is Lacking After Shares Rocket 28%

Full year 2023 earnings: EPS and revenues miss analyst expectations

Insufficient new directors

New minor risk - Share price stability

Genfit S.A., Annual General Meeting, May 22, 2024

Genfit S.A.'s (EPA:GNFT) 26% Price Boost Is Out Of Tune With Revenues

Ipsen Confirms U.S. FDA Grants Priority Review for New Drug Application for Elafibranor for the Treatment of Rare, Cholestatic Liver Disease, PBC

Ipsen and GENFIT Announces Full Results from the Pivotal Phase III ELATIVE Trial

Consensus EPS estimates fall by 15%

Consensus revenue estimates increase by 38%, EPS downgraded

GENFIT Announces Publication in Nature Medicine Confirming the Performance of Its Nash Diagnostic Technology

First half 2023 earnings released: €0.42 loss per share (vs €0.21 loss in 1H 2022)

Health Check: How Prudently Does Genfit (EPA:GNFT) Use Debt?

New minor risk - Profitability

Consensus EPS estimates increase by 291%

Genfit S.A. Announces the Publication of New Data on the Clinical Performance of NIS2+(TM) in Older Patients in Hepatology Communications

New minor risk - Profitability

Price target increased by 9.4% to €9.72

Revenue Downgrade: Here's What Analysts Forecast For Genfit S.A. (EPA:GNFT)

Consensus revenue estimates decrease by 21%

Ipsen and GENFIT Announces Positive Results from Phase III ELATIVE Trial of Elafibranor in Patients with Primary Biliary Cholangitis, A Rare Cholestatic Liver Disease

Price target increased by 9.4% to €9.70

New minor risk - Share price stability

Genfit S.A. (EPA:GNFT) Investors Are Less Pessimistic Than Expected

Price target decreased by 11% to €8.84

GENFIT Presents Phase 1 Clinical Data Evaluating NTZ at Digestive Disease Week as part of its ACLF Program

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Price target decreased by 7.1% to €9.20

Genfit S.A. to Report First Half, 2023 Results on Sep 20, 2023

We Think Genfit (EPA:GNFT) Can Manage Its Debt With Ease

Consensus forecasts updated

New Forecasts: Here's What Analysts Think The Future Holds For Genfit S.A. (EPA:GNFT)

First half 2022 earnings released: €0.21 loss per share (vs €0.21 profit in 1H 2021)

Consensus forecasts updated

Investor sentiment improved over the past week

Downgrade: Here's How Analysts See Genfit S.A. (EPA:GNFT) Performing In The Near Term

Consensus revenue estimates fall by 49%

Price target increased to €10.48

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Consensus revenue estimates increase by 1,016%

Forecast to breakeven in 2022

Consensus forecasts updated

First half 2021 earnings released: EPS €0.21 (vs €1.36 loss in 1H 2020)

Full year 2020 earnings released: €2.61 loss per share (vs €1.76 loss in FY 2019)

Price target increased to €8.30

Full year 2020 earnings released

Genfit's(EPA:GNFT) Share Price Is Down 85% Over The Past Five Years.

Price target raised to €8.20

New 90-day high: €5.20

New 90-day high: €4.76